Instrument Inactif

Autres langues CannPal Animal Therapeutics Limited

Actions

CP1

AU000000CP17

Recherche biotechnologique et médicale

Autres langues

13/04	Argent BioPharma Limited completed the acquisition of 48% stake in Cannpal Animal Therapeutics Limited from AusCann Group Holdings Ltd.
10/03/23	Layton Mills and Margaret Curtis agreed to acquire 52% stake in CannPal Animal Therapeutics Limited from AusCann Group Holdings Ltd for AUD1.
11/03/21	AusCann Group Holdings Ltd completed the acquisition of CannPal Animal Therapeutics Limited from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others.
19/02/21	Cannpal Animal Therapeutics : Narrows Fiscal H1 Loss on Higher Revenue
18/02/21	Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2020
08/01/21	AusCann : CannPal Managing Director to Lead Merged Company Formed With AusCann; CannPal Rises 11%
16/11/20	AusCann Group Holdings Ltd (ASX:AC8) and CannPal Enter Into Scheme of Arrangement
16/11/20	AusCann Group Holdings Ltd entered into a scheme implementation deed to acquire CannPal Animal Therapeutics Limited from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others for AUD 16.9 million.
28/08/20	CannPal Animal Therapeutics Limited Announces Resignation of Max Johnston as Non-Executive Director
21/07/20	CannPal Animal Therapeutics : CBD Substantially Improves Atopic Dermatitis Symptoms in Dogs
21/07/20	CannPal Animal Therapeutics Limited Announces Completion of its Safety and Efficacy Study for DermaCann
10/03/20	CannPal Animal Therapeutics Limited Announces FDA Establishes Investigational New Animal Drug file for CPAT-01
25/02/20	Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2019
05/01/20	CannPal Animal Therapeutics Limited Enters into Exclusive Licensing Agreement with Commonwealth Scientific and Industrial Research Organisation
25/10/19	49,365,405 Ordinary Shares of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.
25/10/19	2,000,000 Options of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.
25/10/19	625,000 Class A Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.
25/10/19	1,500,000 Options of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.
25/10/19	7,250,000 Options of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.
25/10/19	625,000 Class B Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.
25/10/19	625,000 Class C Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.
25/10/19	625,000 Class D Performance Rights of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019.
30/08/19	Cannpal Animal Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2019
31/07/19	CannPal Animal Therapeutics Limited Commences Phase 2 Pilot Study for Cannabis-Derived Osteoarthritis Drug for Dogs
25/02/19	Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2018